Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures
- PMID: 15207740
- DOI: 10.1016/j.bone.2004.02.009
Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures
Abstract
Studies were carried out to characterize the effects of cyclosporines and FK506 on the formation and survival of osteoclasts deriving from mouse bone marrow cultures. Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures. CsA and CsG were approximately equipotent, CsH was approximately one order of magnitude less potent than the other cyclosporines, and FK506 was approximately two orders of magnitude more potent than CsA and CsG. All of the inhibitors demonstrated greater potency and efficacy on decreasing the number of TRAP+ multinucleated cells than on decreasing total TRAP activity. Further evidence that late stages were more sensitive to inhibition was obtained in experiments in which CsA was present for different segments of the RANKL-stimulated culture period. CsA was as efficacious when added for the final 2 days of a 4-day culture as when added for the entire culture period, whereas it was less effective if added for only the first 2 days of the culture. When CsA or FK506 were added for 1 day to cultures in which osteoclasts had already formed, the numbers of TRAP+ osteoclasts decreased. Treatment with CsA or FK506 produced nuclear fragmentation and disruption of the multinucleated osteoclasts and an increase in caspase-3 activity. The apoptosis inhibitor z-VAD partially prevented the inhibitory effects of CsA and FK506 on the survival of TRAP+ multinucleated cells in the cultures and also preserved the normal osteoclast morphology. The data indicate that an important component of the inhibitory effects of CsA and FK506 on marrow-derived osteoclasts is the induction of apoptosis.
Similar articles
-
The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand.Calcif Tissue Int. 2002 Nov;71(5):437-46. doi: 10.1007/s00223-001-1138-3. Epub 2002 Sep 4. Calcif Tissue Int. 2002. PMID: 12202955
-
Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.J Dent. 2005 Oct;33(9):749-55. doi: 10.1016/j.jdent.2005.02.006. Epub 2005 Mar 31. J Dent. 2005. PMID: 16199283
-
Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms.J Endocrinol. 2007 Dec;195(3):415-27. doi: 10.1677/JOE-07-0338. J Endocrinol. 2007. PMID: 18000304
-
Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants.J Dermatol Sci. 1994 Jul;7 Suppl:S47-54. doi: 10.1016/0923-1811(94)90035-3. J Dermatol Sci. 1994. PMID: 7528050 Review.
-
Pharmacological topics of bone metabolism: antiresorptive microbial compounds that inhibit osteoclast differentiation, function, and survival.J Pharmacol Sci. 2008 Apr;106(4):547-54. doi: 10.1254/jphs.fm0070288. J Pharmacol Sci. 2008. PMID: 18431038 Review.
Cited by
-
Roles for NF-kappaB and c-Fos in osteoclasts.J Bone Miner Metab. 2005;23 Suppl:11-5. doi: 10.1007/BF03026317. J Bone Miner Metab. 2005. PMID: 15984408 Review.
-
Calcineurin regulates cyclin D1 stability through dephosphorylation at T286.Sci Rep. 2019 Sep 4;9(1):12779. doi: 10.1038/s41598-019-48976-7. Sci Rep. 2019. PMID: 31484966 Free PMC article.
-
FKBP12: A partner of Snx10 required for vesicular trafficking in osteoclasts.J Cell Biochem. 2019 Aug;120(8):13321-13329. doi: 10.1002/jcb.28606. Epub 2019 Mar 19. J Cell Biochem. 2019. PMID: 30887568 Free PMC article.
-
The role of small molecules in musculoskeletal regeneration.Regen Med. 2012 Jul;7(4):535-49. doi: 10.2217/rme.12.33. Regen Med. 2012. PMID: 22817627 Free PMC article. Review.
-
Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes.Arthritis Res Ther. 2013 Feb 13;15(1):R26. doi: 10.1186/ar4162. Arthritis Res Ther. 2013. PMID: 23406906 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials